Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer.
Saved in:
| Title: | Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer. |
|---|---|
| Authors: | Wander SA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. swander@mgh.harvard.edu., Weipert CM; Guardant Health, Inc., Palo Alto, CA, USA., Cabel L; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Liao J; Guardant Health, Inc., Palo Alto, CA, USA., Zhang N; Guardant Health, Inc., Palo Alto, CA, USA., Safonov A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medicine, New York, NY, USA., Bardia A; UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA., Razavi P; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. razavip@mskcc.org.; Weill Cornell Medicine, New York, NY, USA. razavip@mskcc.org. |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2026 Jun 12. Date of Electronic Publication: 2026 Jun 12. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer |
| Database: | MEDLINE Ultimate |
| ISSN: | 2374-4677 |
|---|---|
| DOI: | 10.1038/s41523-026-00986-1 |
